Rolke James 4
4 · LA JOLLA PHARMACEUTICAL CO · Filed Jun 2, 2020
Insider Transaction Report
Form 4
Rolke James
Chief Scientific Officer
Transactions
- Award
Common Stock
2020-05-29$4.01/sh+205$822→ 81,771 total - Award
Stock Option (Right to Buy)
2020-05-29+205→ 205 totalExercise: $4.72Exp: 2030-05-29→ Common Stock (205 underlying)
Footnotes (2)
- [F1]These shares were acquired on 05/29/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F2]The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.